UNION Therapeutics A/S

▎药明康德内容团队编辑 潜在“first-in-class”特应性皮炎疗法2期临床结果积极 UNION Therapeutics今天宣布，其潜在“first-in-class”口服疗法orismilast在治疗中度至重度特应性皮炎成人患者的2b期临床试验ADESOS中获得积极结果。基于这一进展，该公司计划推进这款疗法进入3期临床试验。  研究中随机分配的233名患者的数据表明，与安慰剂组（n=55）相比，orismilast的20 mg（n=58）、30 mg（n=61）和40 mg（n=59）剂量组在第16周时让更多患者达到了研究者总体评估（IGA）评分为0或1的缓解标准（比例分别为26.3%、24.3%、30.9%和9.5%；所有p<0.05）。此外，所有治疗组在第2周时的瘙痒数值评分（NRS）均表现出显著的≥4点的减轻，与安慰剂相比获得显著改善（p<0.05）。 Orismilast是一种新一代高效磷酸二酯酶4（PDE4）抑制剂，靶向与炎症相关的PDE4B/D亚型，表现出对Th1、Th2和Th17通路的强效抑制作用。它在炎症级联反应的早期阶段起作用，诱导对多种皮肤和免疫疾病相关的多种细胞因子的广泛抗炎作用。Orismilast的开发旨在比上市的PDE4抑制剂具有更强的抗炎特性，这得益于其对PDE4B和D亚型的更高选择性。 新锐完成4600万欧元B轮融资，开发基于慢病毒载体的基因疗法 Genespire今日宣布完成4600万欧元（约5200万美元）的B轮融资，获得资金将支持该公司的核心候选产品GENE202的开发，直至进入治疗甲基丙二酸血症（MMA）的1/2期临床试验。MMA是一种破坏某些氨基酸和脂肪代谢的严重遗传疾病，通常在婴儿早期发病，伴随高死亡率，临床表现包括肌无力、癫痫、发育迟缓和器官损伤。目前，尚无针对MMA的改变疾病进程的治疗方法。 GENE202是一种现货型基因疗法，利用了该公司的免疫屏蔽慢病毒载体（ISLV）平台。GENE202设计为可静脉注射，使患者的肝脏终生产生该疗法。ISLV的作用机制使Genespire的治疗方法特别适用于当前面临最紧迫未满足医疗需求的遗传病儿童患者，同时也能惠及成人患者。 本轮B轮融资还将加强公司产品管线，促进针对多种其他遗传疾病候选疗法的发现和临床前研究。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料： [1] UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment. Retrieved September 25, 2024, from https://www.prnewswire.com/news-releases/union-therapeutics-announce-results-from-the-adesos-phase-2b-study-in-atopic-dermatitis-confirming-the-potential-of-orismilast-as-a-first-in-class-safe-and-efficacious-oral-treatment-302258828.html [2] Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic. Retrieved September 25, 2024, from https://www.genespire.com/wp-content/uploads/2024/09/240925-Genespire-Series-B-press-release-FINAL.pdf 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

Orismilast is a phosphodiesterase-4 (PDE4) inhibitor, which impacts multiple inflammatory mediators causing a pro-inflammatory effect. Image credit: Evgeniia Primavera / Shutterstock. Union Therapeutics is looking to advance its PDE4 inhibitor, orismilast, into a Phase III clinical trial for atopic dermatitis (AD) following positive results from a Phase IIb study for the therapy in the indication. The company is investigating orismilast for multiple dermatological and inflammatory indications , including psoriasis, hidradenitis suppurativa, and ulcerative colitis. Union plans to start a Phase III trial for the therapy in AD once the US Food and Drug Administration (FDA) approves the trial design at an end-of-Phase II meeting. The results from the dose-ranging Phase IIb ADESOS trial (NCT05469464) were presented at the European Academy of Dermatology and Venerology (EADV) 2024 Congress taking place from 25 to 28 September in Amsterdam, Netherlands. “The results from the ADESOS study with orismilast in AD follows positive readouts in psoriasis and hidradenitis suppurativa confirming the potential of orismilast as a safe oral treatment option across immunology,” said Kim Kjøller, co-CEO of Union. Orismilast is a phosphodiesterase-4 (PDE4) inhibitor, which impacts multiple inflammatory mediators causing a pro-inflammatory effect. In 2021, Union licensed out the development and marketing rights to the therapy in China to Innovent Biogics in a deal worth more than $267m. See Also: MHLW approves MSD’s KEYTRUDA for lung and urothelial cancers MHLW approves Eli Lilly’s Kinsula to treat Alzheimer’s in Japan The Phase IIb ADESOS study enrolled 233 patients with moderate to severe atopic dermatitis. The patients received either one of the three doses of orismilast – 20mg, 30mg or 40mg – or a placebo. The trial met its primary endpoint by showing a reduction in eczema area and severity index (ESAI) at 16 weeks. The participants in 20, 30, and 40mg orismilast groups achieved a mean percentage reduction in ESAI of -55.1%, -52.2%, -61.4%, respectively, compared to the -50.4% reduction in the placebo group. The company cited high disease severity at baseline, with a mean ESAI of 23, as the reason for the high ESAI placebo response. The study also met its secondary endpoint of scoring a clear (0) or almost clear (1) response in the Investigator Global Assessment for AD (IGA-AD) at 16 weeks. The 26.3%, 24.3%, and 30.9% participants in 20mg, 30mg, and 40mg orismilast groups achieved 0/1 scores in IGA-AD, compared to 9.5% in the placebo group. The company also noted that treatment groups showed a reduction in CCL17/thymus and activation-regulated chemokine (TARC) skin levels, a biomarker of AD, with “end of treatment levels approaching those of non-lesional skin”. The orismilast groups also observed a four or more-point reduction in the itch numerical rating scale (NRS) two weeks following treatment. The common treatment-associated adverse effects were diarrhoea, nausea and headache.

Orismilast Phase 2b results in atopic dermatitis (AD) presented today as a late-breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) Congress 2024 Orismilast demonstrated clear treatment effect with statistical significance for all dose arms on the registrational endpoint of IGA0/1 at week 16 Orismilast also demonstrated fast onset of itch reduction as measured by ≥4 point reduction in NRS at week 2 with statistical significance for all dose arms Biomarkers including TARC (CCL17) improved statistically significantly for all orismilast doses compared with placebo Safety and tolerability in line with prior studies with orismilast as well as marketed PDE4-inhibitors, positioning orismilast uniquely as a safe and efficacious oral treatment Orismilast has previously demonstrated efficacy in both psoriasis and hidradenitis suppurativa (HS), and is also being studied in ulcerative colitis (UC) Following a positive End-of-Phase 2 meeting with the FDA, UNION plan to progress orismilast to Phase 3 development in AD HELLERUP, Denmark, Sept. 25, 2024 /PRNewswire/ -- UNION therapeutics A/S ("UNION"), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announces results from the ADESOS Phase 2b study with orismilast in adults with moderate to severe atopic dermatitis presented by Prof. Dr. Eric Simpson at the EADV Congress 2024. Data from the 233 patients randomized and dosed in the study demonstrated that significantly more patients achieved Investigator Global Assessment (IGA) 0/1 responses at Week 16 in orismilast 20mg (n=58), 30mg (n=61), and 40mg (n=59) groups, compared to placebo (n=55) (26.3%, 24.3%, 30.9%, and 9.5%, respectively; all p-values <0.05). Additionally, the efficacy observed using the IGA score was supported by changes in skin levels of TARC (CCL17/thymus and activation-regulated chemokine) - a key disease biomarker of AD. Data showed that TARC skin levels are significantly reduced in the active arms, with end of treatment levels approaching those of non-lesional skin. Mean percentage changes in EASI (Eczema Area and Severity Index) at Week 16 were: -55.1%, -52.2%, -61.4%, and -50.4%, in orismilast 20, 30, 40mg and placebo groups, respectively (p>0.05). Mean EASI at baseline was 23, the least severe reported in a Phase 2b/3 study in moderate to severe AD to date. This likely drove the high EASI placebo response also seen in other recent studies with more moderate patients. In the subgroup of patients with severe disease at baseline (EASI >21), active arms separated from placebo on EASI as well as other endpoints. Additionally, all active arms demonstrated a significant ≥4-point reduction in itch Numerical Rating Scale (NRS) at Week 2, compared to placebo (p <0.05). Additional patient-reported outcomes, including change in pain and sleep NRS, as well as patient global impression of change, were significantly improved in the 20 mg group at Week 2. Most patients with AD report itch as the worst symptom of their disease and therefore reporting a fast onset of action on itch and other patient reported outcomes is important to improving patient quality of life. "The results from the ADESOS study with orismilast in atopic dermatitis (AD) follows positive read outs in psoriasis and hidradenitis suppurativa (HS) confirming the potential of orismilast as a safe oral treatment option across immunology", says Kim Kjøller, Co-CEO of UNION. "We are excited that the results have been presented today as a late-breaking oral presentation by Prof. Dr. Eric Simpson at the EADV Congress 2024. It is always a pleasure being at the conference and discussing the results with leading experts within the field as we plan to progress orismilast to Phase 3 development in atopic dermatitis." No new safety signals were identified, and the safety profile was aligned with that seen for the PDE4 class. The most common TEAE's were diarrhea, nausea, and headache, mainly seen within the first month, mostly mild in severity, with few leading to treatment discontinuation. The safety and tolerability profile of orismilast was confirmed and consistent with the PDE4-class and what was seen in the IASOS study of orismilast in psoriasis and OSIRIS study of orismilast in HS. About the ADESOS Phase 2b study The Phase 2b study is a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of orismilast in patients with moderate to severe AD. The study included 235 patients who were randomized to three active doses (20mg, 30mg, and 40 mg) of orismilast or placebo administered twice daily. The study was conducted in centers in Europe and in the US. About orismilast Orismilast is a next generation, high potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It acts early in the inflammation cascade, inducing a broad range of anti-inflammatory effects across multiple cytokines involved in many dermatological and immunological diseases.1) Orismilast is developed to have more potent anti-inflammatory properties than previously marketed PDE4 inhibitors, enabled by higher selectivity for subtypes PDE4B and D. UNION is developing orismilast as an oral treatment, based on the well-known safety profile of the PDE4 class, across immunology, initially targeting best-in-class or first-in-class positions in atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis and ulcerative colitis (UC). The FDA has cleared UNION's Investigational New Drug (IND) application for oral orismilast and granted Fast Track designation for oral orismilast for the treatment of moderate to severe AD as well as for the treatment of moderate to severe HS. About atopic dermatitis AD is a chronic inflammatory skin disease affecting 2.1-4.9 % of the adult population worldwide and is the most common skin disease among children.2) There was approximately 20 million diagnosed moderate-to-severe adult patients with AD in 2023 in the Seven Major Markets (US, France, Germany, Italy, Spain, UK, and Japan).3) Disease symptoms are characterized by recurrent eczematous skin lesions and intense itch. AD has a substantial psychosocial impact on patients and relatives.4) During disease flares, approximately 80% of patients may experience disturbed sleep, which may also disrupt the sleep of family members.5) The disease also appears to impact the mood, and patients have an increased risk of anxiety and depression.6) Sources 1) Blauvelt A et al., Dermatology and Therapy 2023: Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review - PubMed (nih.gov) & Silverberg J.I. et al., JEADV 2022: & Warren R.B. et al., JEADV 2022: 2) Barbarot S et al,. Allergy 2018: 3) EvaluatePharma 2023 4) Laughter MR et al., British Journal of Dermatology 2021: 5) Eichenfield LF et al., Journal of the American Academy of Dermatology 2014: 6) Drucker AM et al., The Journal of Investigative Dermatology 2017: Contacts Morten Boesen, Chief Financial Officer, UNION therapeutics A/S +45 2381 5487 [email protected] Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S +45 5385 3044 [email protected] About UNION therapeutics UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION's lead asset is orismilast, a next generation, high potency PDE4B/D inhibitor, for a range of immunological diseases e.g., atopic dermatitis (AD) and hidradenitis suppurativa (HS). Orismilast holds the potential to become the first safe oral treatment in AD. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at This information was brought to you by Cision WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED